GSK to invest over $800M in Pennsylvania R&D and manufacturing hub

· Health · United States

GSK has budgeted more than $800 million to expand its Pennsylvania footprint, its second expansion in the state in two years. Construction is set to begin in 2027 at its current site, adding research and development plus manufacturing capacity. The investment signals continued commitment to US-based drug development and production at a time when pharmaceutical supply chains and domestic manufacturing capacity are under scrutiny. It follows the company's earlier expansion in the same state, reinforcing Pennsylvania's role in its global network.

Why it matters：Large manufacturing commitments by global drugmakers affect supply resilience and the geography of pharmaceutical production.

Key points

  • The budget exceeds $800 million for the Pennsylvania expansion.
  • Construction begins in 2027 at GSK's current site.
  • It is GSK's second expansion in the state in two years.

Sources (original reporting)

More stories from this day